Virothera

Virothera is an early-stage biotechnology company pioneering a gene therapy platform based on human homologues of viral immune modifiers to reprogram immune cells. The technology targets the core problem of immune dysregulation in persistent conditions like chronic infections, cancer, and autoimmune diseases, with the goal of achieving durable control. Founded in 2020 and based in London, the private company is in the pre-clinical, pre-revenue stage, building its pipeline and team, including recent appointments to its clinical leadership. Its approach represents a potentially disruptive modality in the immunotherapy space, aiming for broader therapeutic reach compared to biologics.

Gene therapy platform using human homologues of viral immune modifiers (VIMs) to reprogram immune cells in vivo.

Virothera competes in the crowded but rapidly evolving fields of immunotherapy and gene therapy, facing competition from large pharma, biotech companies with approved CAR-T and antibody therapies, and numerous gene therapy platforms. Its differentiation hinges on the novelty of its viral homologue-based immune programming, a niche not yet widely explored.